Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumors.
The diphosphonate bone scan is ideally suited to assess many global, focal or multifocal metabolic bone disorders and there remains a role for conventional bone scintigraphy in metabolic bone disorders at diagnosis, investigation of complications, and treatment response assessment. In contrast, the role of bone scintigraphy in the evaluation of primary malignant bone tumors has reduced with the improvement of morphologic imaging, such as computed tomography and magnetic resonance imaging. However, an increasing role for (18)F-fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography is emerging as a functional assessment at diagnosis, staging, and neoadjuvant treatment response assessment.
Cook
Gary J R
GJ
Department of Nuclear Medicine and PET, The Royal Marsden NHS Foundation Trust, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom. gary.cook@rmh.nhs.uk
Gnanasegaran
Gopinath
G
Chua
Sue
S
D001851:Bone Diseases, Metabolic / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D011877:Radionuclide Imaging / Q000379:methods*
D019788:Fluorodeoxyglucose F18